An innovative biopharmaceutical company focused on development and commercialization of medicines to treat renal diseases were in need of an urgent mock Food and Drug Administration (FDA) inspection.
On Novartis' Data Manipulation
by Greg Dombal, Chief Operating Officer
“If this is true” - What does this mean for clinical trials?
By Greg Dombal and Niki Gallo, Halloran Consulting Group
Apple Watch Approval Marks Shift In Device Development And Approvals
In September, the U.S. Food and Drug Administration (FDA) approved the Apple Watch’s electrocardiogram feature, clearing the way for use of the watch as a medical device. This is the latest step in the FDA trying to quickly catch up with the evolution of technology available to consumers going the direction of medical devices.
FDA 483 Action Planning & Remediation
An early stage device company received a 483 with multiple observations after a long two-week BIMO inspection and were in need of strategic support to address findings in a short period of time and develop an action plan for remediation.
The life of a virtual clinical trial participant
I am currently participating in a clinical trial. I have neither seen a physician nor traveled to a site for a procedure. During my first 15 days of trial participation, my samples have been sent 43 times - and I never once had to leave my house for it.
Addressing the rapidly changing clinical landscape
The Cures Act is part of a broader effort by FDA to improve the regulatory process and speed treatments to those in need. Dr. Gottlieb published a blog post affirming FDA’s commitment to hiring staff and meeting the goals of HHS Secretary’s Reimagine FDA directive.
Three Orphan Drug Program problems and how the FDA plans to fix them
When the FDA bestows an “orphan” designation, it validates a product’s potential benefit. However, sponsors can pursue and receive an orphan designation for a pediatric population which waives Pediatric Research Equity Act (PREA) requirements and exempts the product from clinical studies in a pediatric population.
FDA Fast Track designations reach 20th year
Twenty years after its inception, the FDA’s Fast Track designation program is going strong, with many signs that it has achieved its goal of bringing novel drugs to the market faster. Now, even with a new FDA Commissioner at the helm, the Fast Track program is unlikely to change substantially...